The newly proposed clinical care pathway for metabolic dysfunction-associated steatotic liver disease (MASLD) represents an important step toward standardizing the evaluation and management of one of the most prevalent chronic liver diseases globally. MASLD, closely linked to obesity, type 2 diabetes, and other cardiometabolic risk factors, is frequently managed in primary care and endocrinology settings, necessitating practical, scalable approaches to care.
Novo Nordisk has received US regulatory approval for Wegovy® HD (semaglutide 7.2 mg), representing a significant advancement in pharmacological obesity management. This higher-dose formulation of the GLP-1 receptor agonist semaglutide is designed to address unmet needs in patients who do not achieve adequate weight loss with existing therapies. The approval is supported by robust data from the phase 3 STEP UP clinical trial program, which evaluated the efficacy and safety of once-weekly semaglutide 7.2 mg in adults with obesity.
The 2026 consensus statement from the American Association of Clinical Endocrinology reflects a continued evolution in endocrine care, emphasizing a comprehensive, patient-centered, and multidisciplinary framework for managing cardiometabolic diseases. Building on prior AACE guidance and algorithms, the statement integrates the latest evidence with practical clinical strategies to address conditions such as obesity, diabetes, dyslipidemia, and related metabolic disorders.
The 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia represents a major update in lipid management, integrating contemporary evidence to optimize prevention of atherosclerotic cardiovascular disease (ASCVD). The guideline provides a comprehensive, life-course approach to the evaluation, treatment, and monitoring of dyslipidemias, encompassing both primary and secondary prevention strategies.
Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease characterized by joint inflammation, structural damage, and associated skin manifestations of psoriasis. Despite the availability of several biologic and targeted therapies, many patients continue to experience persistent disease activity or treatment intolerance, highlighting the need for additional therapeutic options. Deucravacitinib (Sotyktu), an oral selective tyrosine kinase 2 (TYK2) inhibitor developed by Bristol Myers Squibb, has now received approval from the U.S. Food and Drug Administration for the treatment of adults with active psoriatic arthritis. This approval represents the first TYK2 inhibitor authorized for this indication and introduces a novel mechanism targeting intracellular cytokine signaling pathways involved in immune-mediated inflammation.
Duchenne muscular dystrophy (DMD) is a severe X-linked neuromuscular disorder characterized by progressive muscle degeneration caused by mutations in the dystrophin gene. Z-rostudirsen (DYNE-251) is an investigational exon-51–skipping therapy designed to restore the production of functional dystrophin by enabling targeted delivery of a phosphorodiamidate morpholino oligomer to muscle tissue. Dyne Therapeutics recently reported new cardiopulmonary and long-term clinical results from the Phase 1/2 DELIVER trial evaluating this therapy in individuals with DMD amenable to exon 51 skipping.
Diabetes mellitus is a chronic metabolic disorder with high global prevalence and considerable risk of long-term complications if glucose levels remain uncontrolled. Mobile health (mHealth) interventions—leveraging smartphones, SMS messaging, and telehealth technologies—offer scalable tools for diabetes self-management, patient engagement, and clinical monitoring. This systematic review and meta-analysis aimed to comprehensively evaluate both the clinical efficacy and cost-effectiveness of mHealth interventions in diabetes care.
Glomerular hyperfiltration at the single-nephron level often precedes detectable whole-kidney GFR decline in type 2 diabetes (T2D). Renal functional reserve (RFR), measured as the postprandial GFR increase, may unmask this hidden hyperfiltration. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) like empagliflozin reduce intraglomerular pressure via tubuloglomerular feedback, often causing an initial GFR dip. We hypothesized that lower baseline postprandial RFR predicts greater empagliflozin-induced GFR reduction, but not responses to dipeptidyl-peptidase-4 inhibitor (linagliptin) or sulfonylurea.
Heart failure (HF) represents a prevalent and prognostically important complication in individuals with type 2 diabetes (T2D), contributing substantially to morbidity and mortality. Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefit in T2D, the impact of the once-daily oral semaglutide formulation on HF outcomes has not been fully characterized. The SOUL trial was a multinational, randomized, double-blind, placebo-controlled cardiovascular outcomes study in adults with T2D and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD), originally designed to assess major adverse cardiovascular events (MACE). This secondary analysis evaluates the effect of oral semaglutide on HF outcomes according to HF status at baseline.
The phase 3 CORALreef Lipids trial, a multinational, double-blind, randomized, placebo-controlled study published in the New England Journal of Medicine on February 4, 2026, assessed the efficacy and safety of enlicitide decanoate, an investigational oral macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Enlicitide targets PCSK9 to increase hepatic LDL receptor availability and reduce circulating LDL cholesterol (LDL-C), offering a convenient oral alternative to injectable monoclonal antibodies.
